SCHEMBL280263

SCHEMBL280263

Cc1cnc(C(=O)NS(C)(=O)=O)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 2/20 0.46
APLNR P35414 3/20 0.44
MYC P01106 2/20 0.38
MAP4K4 O95819 1/20 0.35
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35
SCN9A Q15858 6/20 0.35
PTGS2 P35354 2/20 0.35
NLRP3 Q96P20 1/20 0.35
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GRIA1 P42261 1/20 0.33
GRIA2 P42262 1/20 0.33
GRIA3 P42263 1/20 0.33
GRIA4 P48058 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
GRIN2B Q13224 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23771953 0.80 P4HTM (0.43) P4HTMMAP4K4MAPTRAB9ASCN9A
SCHEMBL12179242 0.75 CNR1 (0.42) APLNRMAPTRAB9AHDAC1HDAC6
SCHEMBL31538477 0.74 P2RX7 (0.59) APLNRMAPTRAB9AHDAC1HDAC6
SCHEMBL24911599 0.71 P4HTM (0.36) P4HTMSCN9A
SCHEMBL15632521 0.70 P4HTM (0.41) P4HTMMYCSCN9A
SCHEMBL15070399 0.70 P4HTM (0.50) P4HTMMAP4K4SCN9AHDAC1HDAC6
SCHEMBL19145297 0.69 CNR1 (0.51) RAB9A
SCHEMBL15695582 0.68 SCN9A (0.47) P4HTMMYCSCN9APTGS2HDAC1
SCHEMBL279954 0.68 HDAC1 (0.63) P4HTMRAB9ASCN9APTGS2HDAC1
SCHEMBL18254281 0.68 APLNR (0.47) APLNRMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL P4HTM 446/4885APLNR 75/4885MYC 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.